Victoria M. Villaflor

Victoria M. Villaflor

Hematology | Oncology

101 The City Drive South
Building 23
Orange, CA 92868

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Therapeutic Vaccines for Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma.

Therapeutic Vaccines for Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma.

Journal: Vaccines

Published: February 14, 2026

Evaluating Clinical Factors Including HPV Clearance on Survival Outcomes in HPV+ Oropharyngeal Carcinoma.

Evaluating Clinical Factors Including HPV Clearance on Survival Outcomes in HPV+ Oropharyngeal Carcinoma.

Journal: Cancers

Published: July 08, 2025

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Journal: Journal for immunotherapy of cancer

Published: July 04, 2025

Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors.

Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors.

Journal: Cancer medicine

Published: June 29, 2024

Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors.

Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors.

Journal: Cancer immunology, immunotherapy : CII

Published: May 15, 2024

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.

Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.

Journal: Science advances

Published: October 13, 2023

Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.

Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.

Journal: JCO precision oncology

Published: September 01, 2023

Barriers to and enablers of physical activity participation in lung cancer survivors.

Barriers to and enablers of physical activity participation in lung cancer survivors.

Journal: PM & R : the journal of injury, function, and rehabilitation

Published: August 24, 2023

Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.

Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.

Journal: Clinical lung cancer

Published: June 02, 2023

BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.

BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.

Journal: Cancer gene therapy

Published: May 24, 2023

Implications of updated staging system for p16+ oropharyngeal squamous cell carcinoma: Is valuable prognostic information being omitted?

Implications of updated staging system for p16+ oropharyngeal squamous cell carcinoma: Is valuable prognostic information being omitted?

Journal: Head & neck

Published: April 28, 2023

Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?

Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?

Journal: Current treatment options in oncology

Published: April 24, 2023

Showing 1-12 of 77

Last Updated: 09/26/2026